儿童心脏移植后呼吸道合胞病毒与疫苗可预防感染的住院情况
移植前需机械循环支持、诱导治疗使用≥2种免疫抑制剂以及移植后第一年年龄<2岁与R/VPI住院风险增加相关。
要点
- 儿童心脏移植后R/VPI住院常见,17.9%的受者在随访期间至少发生一次。
- 移植前机械循环支持、诱导使用≥2种免疫抑制剂及移植后第一年<2岁是R/VPI住院的危险因素。
核心结论
- 儿童心脏移植后R/VPI住院发生频繁,并与显著的医疗费用相关。
研究设计与样本
- 采用负二项回归模型调整人口学和临床混杂因素评估R/VPI住院危险因素,总费用调整为2018年美元。
主要发现
- 681例(17.9%)在随访期间发生R/VPI住院,共诊断984次R/VPI,分布于951次住院中,其中440次(44.7%)发生在移植后第一年。
- 最常见病原为RSV(n=380,38.6%)、流感(n=265,26.9%)和肺炎球菌(n=105,10.7%)。
- 调整分析显示,移植前需要机械循环支持、诱导治疗使用≥2种免疫抑制剂以及移植后第一年年龄<2岁的患者R/VPI住院风险增加。
临床怎么用
- 对移植前需机械循环支持、诱导使用≥2种免疫抑制剂及移植后第一年年龄<2岁的高危患儿应加强R/VPI监测与预防。
- 可考虑通过加速免疫接种程序扩大疫苗使用,并研究>2岁儿童使用帕利珠单抗及接种后免疫原性监测与再免疫策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the risk factors for acquiring a respiratory syncytial virus (RSV) and vaccine-preventable infections (R/VPI) in pediatric heart transplant recipients and the associated morbidity and hospital resource use. STUDY DESIGN: Patients <18 years who underwent heart transplantation from September 2003 to December 2018 at hospitals using the Pediatric Health Information System database were identified. Their transplant hospitalization and subsequent hospitalizations for R/VPI through December 2018 were analyzed. Risk factors for R/VPI hospitalizations were evaluated using negative regression binomial models adjusted for demographic and clinical confounders. Total hospital costs were adjusted for 2018 US$. RESULTS: Of 3815 transplant recipients, 681 (17.9%) had an R/VPI hospitalization during 23 746 available person-years of follow-up. There were 984 R/VPIs diagnosed during 951 hospitalizations, and 440 (44.7%) occurred the first year after transplantation. The most common causes were RSV (n = 380; 38.6%), influenza (n = 265; 26.9%), and pneumococcus (n = 105; 10.7%). In adjusted analyses, there was an increased risk of R/VPI hospitalization in patients requiring mechanical circulatory support before transplantation, patients receiving induction with ≥2 immunosuppressive agents, and patients <2 years in the first year after transplantation. The median length of stay for an R/VPI hospitalization was 4 days (IQR, 2-8 days) with a median total cost of $11 081 (IQR, $6215-$24 322). CONCLUSIONS: Hospitalization for R/VPIs occurred frequently after heart transplantation and were associated with significant costs. Potential strategies to minimize R/VPI include expanding vaccine use through accelerated immunization schedules, further studies of use of palivizumab beyond 2 years of age, and immunogenicity monitoring after vaccination with re-immunization based on guidelines.
引用
- Hayes EA, Hart SA, Gowda C, et al. Hospitalizations for Respiratory Syncytial Virus and Vaccine Preventable Infections following Pediatric Heart Transplantation. J Pediatr. 2021. PMID: 34000283. doi:10.1016/j.jpeds.2021.05.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。